4:47 PM
 | 
Jan 31, 2019
 |  BC Week In Review  |  Company News  |  Other News

AbbVie loses $8B in market cap on steeper Humira erosion

AbbVie Inc. (NYSE:ABBV) lost $5.34 to $80.54 on Jan. 25, representing a loss of almost $8 billion in market cap, after announcing it expects a higher rate of erosion in ex-U.S. sales on autoimmune drug Humira adalimumab in 2019 than previously guided. During AbbVie's 4Q18 earnings conference call Jan. 25, EVP and CFO William Chase said the company now expects a 30% decrease in 2019 global...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >